Acquisition of Eukarion Inc expands Proteome Systems' Biomarker & Drug discovery platform
Proteome Systems announced the completion of its acquisition of US-based bio-pharmaceutical company, Eukarion Inc. The acquisition provides the company with an extensive patent portfolio of novel, highly innovative anti-oxidant compounds. Several key Eukarion personnel with extensive experience in pharmaceutical, pre-clinical and clinical development have joined Proteome Systems in its Woburn, MA facility. The company is now poised to enter clinical development of the drug compounds in respect of various dermatological and neurological indications.
This drug compound portfolio complements Proteome Systems' expertise in biomarker discovery, particularly in the areas of inflammatory and neurological disease. Pre-clinical studies using these compounds with animal models have shown that they have potential efficacy for a broad range of diseases. The company will apply its proteomics expertise to these compounds in order to accelerate their development into drug products with proven clinical efficacy.
The portfolio of drug compounds covers topical, injectable and potentially oral forms. Pre-clinical studies have demonstrated the efficacy of two of Eukarion's anti-oxidant compounds in preventing the loss of learning ability in ageing mice. They also decreased the markers of oxidative stress in the brains of the mice, compared with untreated control animals. Pre-clinical studies have also shown that the antioxidant compounds protect neurons in models of Alzheimer's, Parkinson's and stroke, prevent paralysis in models of multiple sclerosis, protect heart tissue in models of heart attack, reduce inflammation.
Other news from the department business & finance
